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Abstract
The filoviruses Ebola virus (EBOV) and Marburg virus (MARV) cause severe hemorrhagic fever in humans for which no vaccines
are available. Previously, a priming dose of a DNA vaccine expressing the glycoprotein (GP) gene of MARV followed by boosting
with recombinant baculovirus-derived GP protein was found to confer protective immunity to guinea pigs (Hevey et al., 2001.
Vaccine 20, 568 /593). To determine whether a similar prime-boost vaccine approach would be effective for EBOV, we generated
and characterized recombinant baculoviruses expressing full-length EBOV GP (GP1,2) or a terminally-deleted GP (GPa-) and
examined their immunogenicity in guinea pigs. As expected, cells infected with the GPa- recombinant secreted more GP1 than those
infected with the GP1,2 recombinant. In lectin binding studies, the insect cell culture-derived GPs were found to differ from
mammalian cell derived virion GP, in that they had no complex/hybrid N-linked glycans or glycans containing sialic acid. Despite
these differences, the baculovirus-derived GPs were able to bind monoclonal antibodies to five distinct epitopes on EBOV GP,
indicating that the antigenic structures of the proteins remain intact. As a measure of the ability of the baculovirus-derived proteins
to elicit cell-mediated immune responses, we evaluated the T-cell stimulatory capacity of the GPa- protein in cultured human
dendritic cells. Increases in cytotoxicity as compared to controls suggest that the baculovirus proteins have the capacity to evoke
cell-mediated immune responses. Guinea pigs vaccinated with the baculovirus-derived GPs alone, or in a DNA prime-baculovirus
protein boost regimen developed antibody responses as measured by ELISA and plaque reduction neutralization assays; however,
incomplete protection was achieved when the proteins were given alone or in combination with DNA vaccines. These data indicate
that a vaccine approach that was effective for MARV is not effective for EBOV in guinea pigs.
Published by Elsevier Science B.V.
Keywords: Filovirus; Ebola virus; Prime-boost; Baculovirus; DNA vaccine

The Filoviridae family contains two genera of highly
pathogenic viruses: Ebola-like viruses, and Marburglike viruses (IUMS, 2000). Currently four viral species
are listed in the Ebola-like virus genus: Cote d’Ivoire
Ebola virus, Reston Ebola virus (REBOV), Sudan
Ebola virus (SEBOV), and Zaire Ebola virus (ZEBOV).
Numerous strains of these viruses have been identified.
One species of Marburg-like viruses has been officially

* Corresponding author. Fax: /1-301-619-2439.
E-mail address: connie.schmaljohn@det.amedd.army.mil (C.S.
Schmaljohn).

designated, Marburg virus (MARV), with several strains
identified. It is likely that as these strains are better
characterized, some of them will be elevated to viral
species. All of the viruses in the family except for
REBOV are highly pathogenic for humans. ZEBOV
caused two major outbreaks of Ebola hemorrhagic fever
(EHF) in 1976 and 1995, during which hundreds of
cases were reported with mortality rates as high as 80/
90% (Peters et al., 1994). SEBOV caused outbreaks in
Sudan in 1976 and 1979 with /300 cases and mortality
/50%. SEBOV appeared in Uganda in 2000 /2001
causing /400 cases of EHF with a mortality rate of /

0168-1702/02/$ - see front matter. Published by Elsevier Science B.V.
doi:10.1016/S0168-1702(02)00338-6
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60%. The ecology and epidemiology of EBOV are
poorly understood and despite attempts to identify the
host species that maintains the virus in nature, it
remains unknown (Le Guenno, 1997; Leirs et al., 1999).
EBOV particles consist of helical nucleocapsids containing approximately 19 Kb of single-strand, negativesense RNA. The viral genome encodes seven structural
proteins, one of which, the glycoprotein GP, forms
spikes on the surface of the virion. GP is a type 1
membrane protein, and is highly glycosylated with Nlinked and O-linked glycans accounting for approximately half of its apparent molecular weight (Feldmann
et al., 1994). Maturation of GP involves posttranslational cleavage of a precursor by a furin-like enzyme to
yield two fragments, GP1 and GP2, which are disulfidebonded (GP1,2) and expressed on the surface of infected
cells and virions (Volchkov et al., 1998a). GP1 is also
shed from the surface of infected cells in a soluble form
and may contribute to the complex pathogenesis of this
virus (Volchkov et al., 1998b).
In addition to mRNA for GP, transcription of the GP
gene leads to mRNA encoding a secreted non-structural
glycoprotein, sGP (Volchkov et al., 1995). The sGP
mRNA is the exact copy of the viral genome, whereas
the mRNA of the mature GP is generated by transcriptional editing, which results in the addition of a nontemplated adenosine residue to a run of seven adenosine
residues (Sanchez et al., 1996). Although the role of sGP
is not completely understood, a study using a ZEBOV
infectious clone, showed that in the absence of sGP,
much of full length GP synthesis is arrested in the
endoplasmic reticulum or Golgi (Volchkov et al., 2001).
These data suggest that high-level expression of GP
overwhelms the transport and glycosylation machinery
of the host cell, resulting in increased cytopathology.
The presence of sGP may temper the GP expression and
cytopathology, allowing the virus to replicate for longer
periods of time (Volchkov et al., 2001). It was speculated
that sGP might also play a role in pathogenesis by
inactivating neutrophils and/or acting as a decoy for
anti-EBOV antibodies (Ito et al., 2001; Maruyama et al.,
1999a; Yang et al., 1998).
Studies to define important immune responses for
protection from EBOV have indicated that both humoral and cell-mediated immunity play critical roles in
disease prevention. GP1,2 is a target for neutralizing
antibodies, which have been shown to be an important
element of immunity to EBOV (Jahrling et al., 1996;
Mikhailov et al., 1994). Moreover, vaccination with
GP1,2 offers protection from lethal EBOV challenge in
rodent models (Gilligan et al., 1997; Pushko et al., 1997,
2000; Sullivan et al., 2000; Vanderzanden et al., 1998;
Xu et al., 1998).
Although a variety of vaccine approaches elicit
protective immune responses in rodents, there are
currently no effective vaccines or therapies for EBOV

infection and EHF in humans. Previous studies on
MARV demonstrated that baculovirus-expressed GP
offered partial protective immunity to MARV challenge
in guinea pigs (Hevey et al., 1997), and that complete
protection could be achieved if a priming dose of a
DNA vaccine expressing MARV GP was given prior to
boosts with the baculovirus expression products (Hevey
et al., 2001). In this study, we sought to determine if a
similar prime-boost vaccine approach would be effective
for EBOV. To answer this question, we first prepared
recombinant baculoviruses expressing full-length ZEBOV GP1,2 or a truncated version of GP from which the
carboxy-terminal anchor region of GP2 is deleted
(GPa-). The full-length GP (GP1,2) gene contains eight
adenosine residues at the editing site, to ensure production of full length GP (Vanderzanden et al., 1998). The
truncated GP gene was constructed by introducing a
stop codon at amino acid position 651 of GP. Both
genes were inserted into the plasmid transfer vector
pAcUW51 (BD Biosciences), behind the polyhedrin
promoter and recombinant baculoviruses were generated by homologous recombination with linear baculovirus DNA as described earlier(Schmaljohn et al.,
1983).The GPa- gene is 78 nucleotides shorter than full
length GP1,2 and encodes a protein that is 26 amino
acids smaller. Analysis of the expression products of our
two recombinant baculoviruses by immune-precipitation and SDS-PAGE revealed that under non-reducing
conditions both the full-length GP1,2 and the truncated
GPa- appear as single bands (/2ME, Fig. 1). Under
reducing conditions, GP1 and GP2 were readily observed
in lysates (not shown) or supernatants of cells infected
with the GP1,2 recombinant (/2ME, Fig. 1A).
Although GP1 was also apparent in samples from cells
infected with the GPa- recombinant, little of the
truncated GP2 expression product was detected in the
infected cells (not shown) or the supernatants (Fig. 1A).
An earlier study using a vaccinia T7 polymerase system,
revealed that a similarly truncated ZEBOV GP1,2 gene
produced secreted, soluble, disulfide-linked GP1,2,
whereas full-length GP1,2 shed predominantly soluble
GP1 into infected cell supernatants (Volchkov et al.,
1998b). In that study, the truncated GP2 was readily
detected in the mammalian cell supernatants by immune
precipitation. We suspect that our differing results with
regard to secreted, truncated GP2 relate to differences in
the ability of the antibodies to recognize the truncated
GP2 proteins, and/or to glycosylation or other processing differences inherent to insect cell propagation that
would result in inefficient complexing of our GP1 and
GP2. Poor complexing would influence the amount of
GP2 that we could detect if our polyclonal antibody
does not specifically recognize GP2, but rather predominantly recognizes epitopes on GP1. This supposition
is supported by Western blot results in which we were
unable to detect GP2 in supernatants of insect cells
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Fig. 1. (A) SDS PAGE of GP1,2 and GPa- expression products from supernatants of recombinant baculovirus-infected insect cells radiolabeled from
30 to 42 h after infection with [35S]cysteine and [35S]methionine and immune-precipitated with anti-EBOV guinea pig sera. The positions of the
disulfide bonded GP1,2 and the individual GP1 and GP2 proteins are indicated with arrows. A radiolabeled protein molecular weight marker (M) was
included on the gel and the apparent molecular weights are indicated in kDa. (B) Immunoblot detection of GP1 secreted into the medium of insect
cells at days 3, 4, or 5 after infection with the recombinant baculovirues. Aliquots of recombinant baculovirus-infected insect cell supernatants were
electrophoresed on SDS-PAGE, then and were electrophoretically transferred to membranes and probed with a polyclonal hyperimmune guinea pig
serum. (C) Immunoblot comparison of EBOV virion proteins to baculovirus-derived GP1,2 and GPa- products. Twenty liter suspension cultures of
Sf9 cells were infected with either the GP1,2 or GPa- baculovirus recombinants and supernatants were collected 48 h later. Aliquots of the
supernatants were concentrated by ultrafiltration and were compared to sucrose gradient-purified EBOV by SDS-PAGE and Western blot using a
polyclonal anti-EBOV hyperimmune guinea pig serum (left panel) or anti-EBOV monospecific guinea pig sera to GP (right panel). Increasing
concentrations of purified EBOV were used in, lanes 1 /4 (left panel). GP1 and nucleocapsid (NP, in virion preparations) are indicated with arrows.
(D) Immune precipitation and SDS-PAGE analysis of baculovirus-derived, radiolabeled EBOV GP1,2 by using five distinct monoclonal antibodies to
EBOV GP.

infected with either the GP1,2 or GPa- recombinant virus
(Fig. 1B). The two bands that migrate between GP1 and
GP2 (Fig. 1A) were non-specifically precipitated from
cell supernatants when testing other baculovirus recombinants, including a construct expressing EBOV NP
using the same polyclonal antibody (data not shown).
Because the GP1 proteins of the two recombinants
should be processed identically, we expect that they
will have the same properties, including the same size as
determined by gel electrophoresis. The apparent slight
migration difference of the GP1 proteins derived from
the two recombinants and immune precipitated (Fig.

1A) may be due to differences in the amount of protein
on the gel, as no migration differences are seen when the
proteins are assayed by Western blot (Fig. 1B and C).
Comparing the EBOV proteins present in cell supernatants by Western blot (Fig. 1B) revealed that approximately fourfold more GP1 was secreted from cells
infected with the GPa- recombinant as compared those
infected with the GP1,2 recombinant as determined by
densitometry. We theorized that the size differences of
the baculovirus insect cell culture-derived proteins and
authentic EBOV proteins observed by Western blot
could be due to glycosylation differences. Insect cells are
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known to have limited capability to process complex
carbohydrates (Jarvis and Finn, 1995) and earlier
studies with recombinant baculoviruses expressing
MARV GP showed differences in glycosylation between
authentic and baculovirus-derived GP as determined by
lectin binding assays (Hevey et al., 1997). Using the
same lectin binding methods, we compared the oligosaccharide moieties on authentic gradient-purified
EBOV and the baculovirus expression products. Virion
GP was found to react most strongly with Datura
stramonium agglutinin (DSA), indicating the presence
of complex or hybrid N-linked glycans. In addition, it
reacted, albeit weaker, with Arachis hypogaea (peanut)
agglutinin (PNA), which recognizes unsubstituted galactose b(1/3)N-acetylgalactosamine cores in O-glycans, and Maackia amurensis agglutinin (MAA) which
reacts specifically with a(2/3)-linked sialic acid, demonstrating the presence of unsubstituted O-glycans and
oligosaccharides containing sialic acid, respectively. The
ZEBOV virion GP did not react with Galantus nivalis
agglutinin (GNA), indicating the absence of high
mannose N-linked glycans.
In contrast to ZEBOV virion GP, baculovirus-derived
GP, either cell-associated or secreted, reacted most
strongly with GNA, indicating modification primarily
by high-mannose oligosaccharides. Similar to our observation with ZEBOV virion GP, the baculovirusderived GP reacted weakly with PNA, denoting the
presence of unsubstituted O-linked oligosaccharides.
Baculovirus-derived GPs did not react with DSA,
MAA, or Sambucus nigra agglutinin (SNA) (which
reacts specifically with a(2 /6)-linked sialic acid) indicating the absence of complex/hybrid N-linked glycans, or
those containing sialic acid. Therefore, as demonstrated
for MARV, the baculovirus derived EBOV GPs have
both O-linked and N-linked carbohydrates, but these
carbohydrates differ from those found in ZEBOV, and
the differences could be the reason for the apparent size
discrepancies of the insect-cell derived and mammalian
cell-derived proteins.
To determine if the glycosylation differences or other
modifications of the GP proteins expressed in insect cell
cultures, affected antigenic changes we analyzed the
recombinant proteins by immune-precipitation with a
panel of monoclonal antibodies that recognize five
distinct epitopes on GP1 (Wilson et al., 2000). We found
that all five antibodies precipitated the baculovirusderived GP1 from the GP1,2 construct (Fig. 1D) or from
the GPa- construct (data not shown). As described
earlier for these monoclonal antibodies (Wilson et al.,
2000), GP2 was also precipitated from the GP1,2
construct, presumably because it remains disulfide
bonded to GP1. No GP2 was detected in cells infected
with the GPa- construct (not shown), consistent with
results presented in Fig. 1A. Epitopes bound by the
antibodies in competition groups 1, 2 and 3 (Fig. 1D)

recognize linear epitopes on GP1, but those in groups 4
and 5 are conformational epitopes (Wilson et al., 2000).
These studies suggest that the antigenic structure of the
baculovirus-derived GPs remains intact.
To assess the immunogenicity of the baculovirusderived EBOV proteins, we first performed a pilot
vaccine study in which small groups of guinea pigs
were vaccinated with various preparations of baculovirus-derived EBOV GP and GPa- proteins. We found
that expression products from both the full-length and
truncated GP genes elicited antibodies to GP and
conferred partial protection from viral challenge (data
not shown). These results were similar to those obtained
with baculovirus-derived MARV proteins (Hevey et al.,
1997). To determine if, as observed for MARV, a primeboost combination of a DNA vaccine and the baculovirus-derived protein could provide better protective
immunity than either vaccine alone in the guinea pig
model, we vaccinated inbred guinea pigs and challenged
them with ZEBOV.
The DNA vaccine or control plasmid were precipitated onto gold beads and loaded into plastic gene gun
cartridges as previously described (Vanderzanden et al.,
1998). Groups of six strain 13 guinea pigs received DNA
only, baculovirus-derived ZEBOV GP1,2 or GPa- only,
or a combination of the two vaccines. For DNA
vaccinations, guinea pigs received 2.5 mg of DNA at
two inoculation sites delivered by the PowderJect-XR
gene delivery device, as previously described (Vanderzanden et al., 1998). Guinea pigs that received baculovirus-derived antigens were vaccinated subcutaneously
at two dorsal sites with a total volume of /0.5 ml
(approximately 5 mg ZEBOV GP or GPa- per animal). A
total of three vaccinations were administered at 4-week
intervals. For the prime-boost vaccinations, groups of
six guinea pigs received a priming dose of the DNA
vaccine followed by two booster doses of the baculovirus products in adjuvant. A control group received a
DNA vaccine consisting of an empty DNA plasmid.
Blood samples were collected at the time of each
vaccination and 2 weeks after the final vaccination.
Serum antibody titers to purified ZEBOV were determined for each guinea pig by ELISA (Hevey et al., 1997;
Vanderzanden et al., 1998) and geometric mean titers
(GMT) for each vaccine group were calculated (Table
1). After the first vaccination, only guinea pigs receiving
the GP1,2 vaccine had detectable antibody responses to
ZEBOV. After the second vaccination antibody responses were detected in all groups except the negative
control group, and after the final vaccination, all groups
had GMT by ELISA ]/log10 (data not shown).
Three weeks after the third vaccination, guinea pigs
were challenged with 1000 PFU of guinea pig-adapted
ZEBOV and observed daily for 28 days for signs of
illness and mortality. Seven days after challenge, blood
samples were collected from the guinea pigs and plaque
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Table 1
Vaccination and challenge of guinea pigs
Prime vaccine Boost vaccine Log10 ELISA titera nAb/totalb (PRNT80) Survivors/totalc Viremiad (viremic/total) Mean day of death (range)
GP DNA
Control DNA
GP DNA
GP DNA
Baculo GP1,2
Baculo GPa-

GP DNA
Control DNA
Baculo GP1,2
Baculo GPaBaculo GP1,2
Baculo GPa-

3.0
NA
3.7
3.9
3.6
3.3

1/6 (1:40)
0/6 (NA)
1/6 (1:40)
4/6 (1:80)
4/6 (1:40)
4/6 (1:60)

1/6
0/6
0/6
2/6
3/6
1/6

3.7 (5/6)
4.4 (6/6)
2.7 (4/6)
3.1 (3/6)
(0/6)
2.8 (3/4)e

12 (10 /18)
9 (8 /10)
12 (10 /16)
12 (10 /13)
17 (14 /19)
8 (6 /12)

a

Geometric mean titers after three vaccinations.
Number of guinea pigs that developed neutralizing antibodies after three vaccinations/total (nAb/T) and the dilution of serum that resulted in
80% plaque reduction in a neutralizing antibody test. Where ]/2 animals were positive an average was calculated.
c
Survivors/total on Day 28 after s.c. challenge with 1000 PFU guinea pig adapted EBOV.
d
Viremia (Log10 PFU/ml) 7 days after challenge. Where ]/2 animals were viremic, a geometric mean titer was calculated.
e
Serum was collected from four surviving guinea pigs, the other two had already succumbed to infection.
b

assays were performed to measure viremia. All of the
control guinea pigs had high viremias and died between
eight and 10 days after challenge (Table 1). Five of the
six DNA-vaccinated guinea pigs were viremic and died,
although levels of viremia were slightly lower than
observed in controls, and death was delayed in most
animals (Table 1). The guinea pigs that received the
baculovirus-derived GP1,2 did not have detectable
viremia at 7 days after challenge; however, all of these
guinea pigs became sick later in the study and three of
six died with a delayed mean time to death as compared
to controls. The guinea pigs that received a priming dose
of the DNA vaccine followed by two additional
vaccinations with the baculovirus derived GP1,2 or
GPa- in adjuvant had reduced levels of viremia as
compared to the controls; however, only two of the
twelve guinea pigs, both in the GPa- group, survived the
challenge. The time to death was also delayed for most
of these guinea pigs (Table 1). All of the surviving
guinea pigs showed increases in antibody levels when
assayed by ELISA 44 days after challenge, indicating
that all had been infected, and that sterile immunity was
not achieved with any of the vaccines.
Neutralizing antibody responses to EBOV have been
suggested to play a role in protective immunity (Jahrling
et al., 1996; Maruyama et al., 1999b; Wilson et al.,
2000), although correlation of neutralizing antibody
levels and protection has not been reported. In our
study, only one of the guinea pigs in the groups that
received the DNA alone or the DNA followed by the
GP1,2, boost had detectable neutralizing antibodies, and
neither survived the challenge. In the two groups that
received the baculovirus proteins in adjuvant, four of six
guinea pigs in each group had PRNT80% titers of 1:40 or
greater. However, there was no correlation with protection. For example, the lone survivor in the GPa- group
did not have detectable neutralizing antibodies, and only
one of three survivors in the GP1,2, group had detectable
neutralizing antibodies. The best neutralizing antibody
responses were obtained in guinea pigs given the GP1,2,

DNA prime followed by the GPa- boost, with four of six
animals having PRNT80% ]/1:40. Nevertheless, there
was little, if any correlation with protection. One of
the two survivors had a reasonably high PRNT80% titer
(1:160), but the other survivor did not have detectable
neutralizing antibodies.
The type of immune response needed to protect from
filovirus challenge is not completely understood, however, it is likely that both strong cellular and humoral
immune responses are needed. Generally, gene gun
delivered DNA vaccines have been characterized as
eliciting CD4/ Th2-type immune response in mice, as
reflected by a predominant IgG1 antibody response. In
contrast, intramuscular injection of a DNA vaccine
elicits a mostly Th1-type response (Feltquate et al.,
1997; Pertmer et al., 1996). This generalization has led to
a feeling that gene gun delivery is better when the
outcome desired is a strong antibody response than
when a strong cell-mediated immune response is needed.
However, we found that gene gun delivered EBOV
DNA elicited cytotoxic T lymphocyte responses in mice
(Vanderzanden et al., 1998). Measuring a cell-mediated
immune response is more difficult in guinea pigs than
mice, and the significance of indirect measures, such
antibody isotypes, which correlate with Th1-like or Th2like responses in mice, are not defined for guinea pigs.
Consequently, as a measure of the ability of the
baculovirus-derived proteins to elicit cell-mediated immune responses, we evaluated the T-cell stimulatory
capacity of the baculovirus-expression products in
cultured human dendritic cells and monocytes as
described previously (Saikh et al., 2001). Briefly, dendritic cells or monocytes were incubated with autologous T cells and supernatants from baculovirus-infected
cell cultures containing EBOV GPa-. These T cells were
then used as effector cells in a cytotoxicity assay using
HLA-matched or -unmatched B cell target cells that had
been pulsed with supernatants from baculovirus infected
cell cultures containing EBOV GPa-, an unrelated viral
antigen, or no antigen. Although we assayed both GP1,2

192

J.L. Mellquist-Riemenschneider et al. / Virus Research 92 (2003) 187 /193

Table 2
T-cell stimulatory capacity of GPa- in cultured human dendritic cellsa
Percent cytotoxicity
DC activated CTL

Monocytes
b

Effector(T cell):target (BSM cell)
1:1

10:1

1:1

10:1

Targets (Experiment 1)
BSM, no antigenc
BSM/GPaBSM/control supernatant
K562d/GPa-

30
29
12
8

26
53
2
24

26
16
0
3

28
38
2
18

Targets (Experiment 2) e
BSM, no antigen
BSM/GpaBSM/control antigen

15
30
11

20
64
12

N/Df
N/D
N/D

N/D
N/D
N/D

a
Adherent monocytes from a HLA-A2 donor were cultured with IL-15 for 60 h to transform them into dendritic cells (DC). Cells were washed
extensively to remove IL-15 and nonadherent cells. Monocytes cultured without IL-15 remain as monocytes throughout culture. Autologous T cells
and Antigens (10 mg/ml) were added to the culture. After 6 days, T cells were collected and used as effector cells in cytotoxicity assays.
b
Effector cell (T cell) to target cell (BSM cell) ratio.
c
BSM (B cell, HLA-A2) were pulsed with Ebola Gpa- (10 mg/ml) culture supernatants or supernatants from cells infected with a wild-type
baculovirus (control in Experiment 1), or culture supernatant from a baculovirus expressing an unrelated protein (Experiment 2) for 1 h at 37 8C and
used as target cells.
d
non-HLA matched control target cells (K562 cells).
e
Experiment 1 and Experiment 2 are similar assays except that DC-activated effector CTLs for experiment 1 were made by culturing autologous T
cells with DC and Ebola antigen wheras in experiment 2 autologous T cells were cultured with DC infected with a VEE replicon expressing EBOV
GP.
f
Not determined (N/D).

and GPa- concentrated from insect cell culture supernatants, the background reactivity of the GP1,2 preparations was too high to achieve valid results. This is likely
due to the lower concentration of the expression product
in the supernatant as compared to that in supernatants
from cells infected with the GPa- baculovirus.
In two independent assays performed with the GPaexpression product, we observed zero to twofold increases in cytotoxicity in HLA-matched cells when we
used an effector:target ratio of 1:1 (Table 2). When the
effector:target ratio was increased to 10:1, a twofold
increase in cytotoxicity was measured in one experiment
and a greater than threefold increase was seen in the
second experiment. No increase in cytotoxicity was seen
in pulsed HLA-unmatched cells or with a control
antigen at either effector:target ratio. Monocyte activated CTLs were also evaluated in one of the assays and
revealed that EBOV GPa- induced a 1.4-fold increase in
cytotoxicity over background at an effector:target ratio
of 10:1. An enhanced cytotoxicity of monocyte activated
CTLs was not seen at the 1:1 effector:target ratio (Table
2). These data provide evidence that the baculovirus
derived GPa- expression product could potentially elicit
not only humoral responses, but also cell-mediated
responses to EBOV. These results, indicate that the
baculovirus-derived proteins are able to elicit cytotoxic

T cell responses in human cells, and presumably also in
guinea pigs.
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